This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy?

On November 14, Austin-based Saturn V Capital Management disclosed a new position in Pharvaris N.V. (PHVS), acquiring 886,332 shares valued at approximately $22.1 million during the third quarter.According to a Securities and Exchange Commission (SEC) filing dated November 14, Saturn V Capital Management initiated a new position in Pharvaris N.V. (PHVS). The fund reported holding 886,332 shares valued at $22.1 million at quarter-end. This addition expanded its total reportable U.S. equity positions to 17 as of September 30, bringing total fund AUM to $456 million.The PHVS stake represents about 4.9% of Saturn V Capital Management LP's 13F AUM.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool